ELOVL5 and posterior cortical atrophy: Further, knockdown of ELOVL5 by siRNA in LNCaP/AR-shp53/shRB cells or CRISPR-Cas9 in C4-2/MDVR cells, both enzalutamide resistant PCa cell lines, increased their enzalutamide sensitivity (Figure 3D,E).